Neodymium-140 DOTA-LM3
Severin, Gregory W; Kristensen, Lotte K; Nielsen, Carsten Haagen; Fonslet, Jesper; Jensen, Andreas I; Frellsen, Anders F; Jensen, K M; Elema, Dennis R; Maecke, Helmut; Kjær, Andreas; Johnston, Karl; Köster, Ulli
Published in: Frontiers in Medicine

DOI: 10.3389/fmed.2017.00098

Publication date: 2017

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Severin, G. W., Kristensen, L. K., Nielsen, C. H., Fonslet, J., Jensen, A. I., Frellsen, A. F., ... Köster, U. (2017). Neodymium-140 DOTA-LM3: Evaluation of anGenerator for PET with a Non-Internalizing Vector. DOI: 10.3389/fmed.2017.00098
Neodymium-140 DOTA-LM3: Evaluation of an In Vivo Generator for PET with a Non-Internalizing Vector

Gregory W. Severin1,2,3*, Lotte K. Kristensen4, Carsten H. Nielsen4, Jesper Fonslet1, Andreas I. Jensen1, Anders F. Frellesen1, K. M. Jensen1, Dennis R. Elema1, Helmut Maecke5, Andreas Kjær4, Karl Johnston6 and Ulli Köster6,7

1 Hevesy Laboratory, DTU Nutech, Technical University of Denmark, Roskilde, Denmark, 2 Department of Chemistry, Michigan State University, East Lansing, MI, United States, 3 Facility for Rare Isotope Beams, Michigan State University, East Lansing, MI, United States, 4 Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 5 Department of Nuclear Medicine, University Hospital Freiburg, Freiburg, Germany, 6 ISOLDE, CERN, Geneva, Switzerland, 7 Institut Laue-Langevin, Grenoble, France

*Correspondence: Gregory W. Severin gwseverin@chemistry.msu.edu

The demand for long-lived positron emitting radiolanthanides is growing due to the success of targeted internal radiotherapy with 177Lu, and the promise of other therapeutic lanthanides such as Auger electron emitters 165Er, and 135La or combined beta-/Auger electron emitters such as 161Tb (1–5). Neodymium-140 (140Nd, t1/2 = 3.4 days) decays to praseodymium-140 (140Pr, t1/2 = 3.4 min), has promise as an in vivo generator for positron emission tomography (PET). However, the electron capture decay of 140Nd is chemically disruptive to macrocycle-based radiolabeling, meaning that an in vivo redistribution of the daughter 140Pr is expected before positron emission. The purpose of this study was to determine how the delayed positron from the de-labeled 140Pr affects preclinical imaging with 140Nd. To explore the effect, 140Nd was produced at CERN-ISOLDE, reacted with the somatostatin analogue, DOTA-LM3 (1,4,7,10-tetraazacyclododecane, 1,4,7-triacetic acid, 10-acetamide N-p-Cl-Phe(cyclo(d-Cys-Tyr-d-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)d-Tyr-NH2) and injected into H727 xenograft bearing mice. Comparative pre- and post-mortem PET imaging at 16 h postinjection was used to quantify the in vivo redistribution of 140Pr following 140Nd decay. The somatostatin receptor-positive pancreas exhibited the highest tissue accumulation of 140Nd-DOTA-LM3 (13% ID/g at 16 h) coupled with the largest observed redistribution rate, where 56 ± 7% (n = 4, mean ± SD) of the in situ produced 140Pr washed out of the pancreas before decay. Contrastingly, the liver, spleen, and lungs acted as strong sink organs for free 140Pr. Based upon these results, we conclude that 140Nd imaging with a non-internalizing vector convolutes the biodistribution of the tracer with the accumulation pattern of free 140Pr. This redistribution phenomenon may show promise as a probe of the cellular interaction with the vector, such as in determining tissue dependent internalization behavior.

Keywords: in vivo generator, 140Nd, 140Pr, internalization, positron emission tomography, DOTA-LM3

INTRODUCTION

The demand for long-lived positron emitting radiolanthanides is growing due to the success of targeted internal radiotherapy with 177Lu, and the promise of other therapeutic lanthanides such as Auger electron emitters 165Er, and 135La or combined beta-/Auger electron emitters such as 161Tb (1–5). Neodymium-140 (140Nd, t1/2 = 3.4 days) decays to praseodymium-140 (140Pr, t1/2 = 3.4 min) by
electron capture with no emission of gamma photons (Figure 1) (6). Because $^{140}\text{Pr}$ has a 51% positron branch ($E_{\text{mean}} = 1.07 \text{ MeV}$) and a short half-life, the pair has potential for long-lived positron emission tomography (PET) tracing of pharmaceuticals. Together as a so-called in vivo generator (7, 8), they provide a high positron yield with lanthanide labeling chemistry and a parent half-life that is suitable for monoclonal antibody, nanoparticle, and peptide imaging (9, 10). In this light, it is interesting to pursue development of $^{140}\text{Nd}$ to investigate how the delayed positron emission from $^{140}\text{Pr}$ affects medical imaging, and how it can be exploited.

The radionuclide $^{140}\text{Nd}$ is non-standard in radiopharmacy, but can be produced in a variety of methods: via $(p,2n)$ reactions on naturally monoisotopic praseodymium-$^{141}$ (11), $^3\text{He}$ bombardment of natural cerium (11–13), or by spallation processes on tantalum (14). Due to the relatively lower volatility of temperature of the rare earths (compared to tantalum), it is possible to extract the spallation-induced radiolanthanides by thermal diffusion and separate them by mass, e.g., at the on-line separator ISOLDE at CERN (15, 16). In principle, this leads to the highest possible specific activity for radiochemistry and has been successfully employed in previous experiments with radiolanthanides (3, 17, 18). The $(p,2n)$ production method is attractive for future developments because it is a reaction that is reachable by biomedical and cyclotron tracers. However, it requires very high purity praseodymium starting material (without neodymium contamination), and a robust lanthanide separation technique in order to achieve radiolabeling with high specific activity.

When considering $^{140}\text{Nd}$ for PET, its value for direct imaging hinges upon the chemical and kinetic profile of the positron producing daughter nuclide $^{140}\text{Pr}$. Previous reports show that the EC decay of DOTA-bound $^{140}\text{Nd}$ is highly efficient at releasing the daughter $^{140}\text{Pr}$ from the chelate, making it available for further interactions as a Pr$^{3+}$ cation (13). Praseodymium and neodymium have remarkably similar chemistry, and under the right conditions Pr$^{3+}$ could be predicted to re-bind a free chelator after being released. However, an activation barrier to stable binding between lanthanide ions and DOTA precludes room temperature chelation of the Pr$^{3+}$ daughter. Other chelators such as DTPA are not inhibited by an activation barrier and may fare better at retaining the daughter praseodymium. The mobility of the daughter praseodymium determines how different the distribution of the tracer-bound parent is from the distribution of the unbound daughter, the evaluation of which will determine the value of $^{140}\text{Nd}/^{140}\text{Pr}$ with functionalized DOTA in vivo. The current set of experiments serves as a preliminary investigation into the $^{140}\text{Nd}/^{140}\text{Pr}$ in vivo PET generator.

In order to create the appropriate scenario to test $^{140}\text{Nd}/^{140}\text{Pr}$, the somatostatin receptor was selected as the target. The reason for this is threefold. First, somatostatin analogs are already employed clinically with the therapeutic radionuclide $^{177}\text{Lu}$ (19) and the diagnostic radionuclides $^{64}\text{Cu}$ (20) and $^{68}\text{Ga}$, where a long-lived positron emitting lanthanide could prove useful in dose determinations. Second, the depth of research into somatostatin receptors has led to the development of well-established internalizing vectors (21), such as DOTATATE, and non-internalizing vectors (22) such as DOTA-LM3 (23, 24). And third, the receptor is expressed in the pancreas, but not in many other tissues: thereby providing a test-tissue with more realistic perfusion than xenograft tumors. In the present study, testing was performed with DOTA-LM3 anticipating that the redistribution of praseodymium would be most evident with a targeting vector that remained located on the surface of the targeted cells.

Herein, we present the results from $^{140}\text{Nd}$-DOTA-LM3 PET quantifications in H727 xenograft tumor-bearing mice before and after euthanasia. The pre- and post-mortem images represent the daughter and parent radionuclide distributions, respectively. As positrons are only emitted by the daughter, PET scanning only reveals the parent distribution in the absence of biological processes that differentiate the vector bound parent from the daughter. We also show verification of the dislocation (also referred to as de-labeling) of $^{140}\text{Pr}$ from DOTA-LM3 by radio-HPLC. Furthermore, ex vivo biodistributions from $^{140}\text{Nd}$-DOTA-LM3 and $^{140}\text{Nd}$ as the free ion are used to show the source and sink organs for the free praseodymium daughter.

MATERIALS AND METHODS

**General**

All water was 18 MΩ cm MilliQ purified and was used to produce all aqueous solutions. Hydrochloric acid solutions were prepared from concentrated HCl (TraceSelect, Sigma).

**Production of $^{140}\text{Nd}$**

A 55 g/cm² tantalum foil target was irradiated by a 1.4 GeV proton beam, creating a multitude of radioactive and stable spallation products. The product nuclei, lanthanides in particular, diffused from the ≈2,000°C target to a ≈2,000°C tungsten surface ionizer. The ions were extracted at 30 kV and mass-separated with a 70° sector magnet (1.5 m mean bending radius). The A = 140 beam was implanted into two Zn-coated gold foils. The zinc, totaling 2–3 mg had been electrodeposited onto the gold foils over

![Figure 1](https://www.frontiersin.org) The decay scheme of $^{140}\text{Nd}$ and its daughter $^{140}\text{Pr}$. 

$^{140}\text{Nd}$ DOTA-LM3
approximately 0.5 cm². The entire procedure is nearly identical to the methodology recently described for projects collecting Tb isotopes at ISOLDE (3, 17).

Radiochemistry

The following methodology was carried out two times with small variations between each run.

The zinc layer containing ¹⁴⁰Nd was etched briefly with aq. HCl (200 µL, 2 M), and the resulting solution was diluted to 2.2 mL with aq. HCl (2 M). This was heated to 98°C, cooled, and passed over AG1X8 anion exchange resin (300 mg, BioRad, 200–400 mesh, initially formate-form) packed in a 4 mm internal diameter (ID), fritted polypropylene column (Supelco) that had been prepared by three times sequential washing with water (3x bed volume), 2 M HCl (3x bed volume), and 6 M HCl (3x bed volume), finishing with equilibration in 2 M HCl. The resin has a high affinity for [ZnCl₄]²⁻ ions in 2 M HCl (25) and was intended to remove any zinc impurity from the ¹⁴⁰Nd. An additional 0.5 mL of 2 M HCl was used to rinse residual ¹⁴⁰Nd from the column, and the entire effluent was collected and adjusted to pH 5–6 with aq. ammonium acetate (1 M, pH 7) and aq. ammonium hydroxide (28%, TraceSelect, Sigma) to a final acetate concentration of roughly 200 mM. This solution was washed with aq. CH₃COONa:CH₃OH (1:1). Unreacted ¹⁴⁰Nd remained at the origin, and ¹⁴⁰Nd-DOTA-LM3 moved to Rf ~0.5.

PET Imaging and Ex Vivo Biodistributions

NCI-H727 lung carcinoid cancer cells (ATCC CRL-5815, LGC Standards) were cultured in RPMI-1640 media supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (Invitrogen) at 37° C and 5% CO₂. Cells in their exponential growth phase and at 80–90% confluence were harvested by trypsinization and resuspended in 1:1 media and matrigel (BD Biosciences) at 5 × 10⁶ cells/mL. Subcutaneous tumors were established in female NMRI nude mice (Taconic, Denmark) by inoculation of 5 × 10⁶ cells in 100 µL on each flank above the hind limbs in the subcutaneous space. All animal experiments were performed under a protocol approved by the National Animal Experiments Inspectorate of Denmark.

Longitudinal small animal PET/CT imaging (Inveon Multimodality PET/CT scanner, Siemens) was performed with NCI-H727 tumor bearing mice injected intravenously with 3.3–4.3 MBq ¹⁴⁰Nd-DOTA-LM3 (n = 8) or 2.7–3.1 MBq ¹⁴⁰Nd-chloride (n = 3) in 150 µL. Mice were anesthetized with sevoflurane (Abbott Laboratories) during injection and PET/CT imaging. PET data was acquired for 600 s in list mode at 1, 3, and 16 h after injection. The mice were sacrificed after the 16 h time-point and a PET acquisition was performed 2 h post-mortem. Images were reconstructed using a 3D maximum a posteriori algorithm with CT based attenuation correction. CT images were acquired with the following settings: 300 projections, 65 kV, 500 µA, and 400 ms exposure, and reconstructed with an isotropic voxel size of 105 µm. Image analysis was performed using the Inveon Software (Siemens). Region of interests (ROIs) were drawn manually on the tumor regions and other organs based on the CT images and the uptake of ¹⁴⁰Nd-DOTA-LM3 or ¹⁴⁰Nd-chloride quantified as % injected dose per gram tissue (%ID/g).

HPLC Verification of De-Labeling and RadioTLC for Determination of Radiochemical Purity

Samples of ¹⁴⁰Nd-DOTA-LM3 were injected onto a reverse-phase C-18 (Luna 3uC18(2)(n) 100 A 100 × 2 mm 3 µm, Phenomenex) column at a flow rate of 0.5 mL/min starting from 0% acetonitrile in water, and reaching 100% over a 15 min gradient. Elution was monitored with a radio detector. The entire effluent was collected in 1 min intervals (500 µL each) and quantified 4 days after collection by liquid scintillation counting on a HIDEX 300 SL spectrometer.

RadioTLC was performed by spotting 1 µL of the DOTA-LM3 solutions (before and after C-18 purification) onto aluminum-backed silica TLC sheets. The sheets were eluted in 10% (w/v) aq. CH₃COONa:CH₃OH (1:1). Unreacted ¹⁴⁰Nd remained at the origin, and ¹⁴⁰Nd-DOTA-LM3 moved to Rf ~0.5.

RESULTS AND DISCUSSION

Isolation of ¹⁴⁰Nd at ISOLDE, Radiochemical Purification, and Radiolabeling of ¹⁴⁰Nd-DOTA-LM3

¹⁴⁰Nd was produced by 1.4 GeV proton induced spallation of tantalum at ISOLDE. The process for vaporization and ionization of lanthanides at the ISOLDE facility is well described (15), and proceeded without complication. The electromagnetic separation of proton rich A = 140 spallation products led to a total...
of about 530 MBq (in two productions) of >99% radionuclidic purity $^{140}$Nd in two Zn-coated gold foils. The $^{140}$Nd implanted foils were briefly etched (without fully dissolving the entire Zn layer) withaq. hydrochloric acid (HCl, 2 M) and the carrier Zn (approximately 1 mg Zn$^{2+}$ in 2 mL 2 M HCl) was removed by passage over AG1x8 anion exchange resin. ICP-OES measurement showed that Zn was completely adsorbed onto the resin, with <30 ng Zn remaining in the purified $^{140}$Nd stock solution (~60 MBq). $^{140}$Nd was concentrated by trap-and-release on a small mixed-bed hydroxamate/carboxylate-functionalized resin. Trapping was only efficient after heating the solution for several minutes at 95°C, indicating that the $^{140}$Nd may not have been completely dissolved during the initial Zn etching. When the 2 M HCl etch solutions containing the Zn were heated prior to purification, the trapping on the hydroxamate/carboxylate resin exceeded 99% efficiency. The release of $^{140}$Nd from the resin was accomplished by elution withaq. HCl (600 µL, 0.1 M) at 98% efficiency.

The eluted $^{140}$Nd was reacted with DOTA-LM3 in ammonium acetate buffer (300 mM, pH 4.8), and after 30–60 min at 95°C radioTLC indicated that $^{140}$Nd-DOTA-LM3 had formed in a 75% radiochemical yield. Quenching with DTPA and C-18 sep-pak purification led to an ultimate combined radiochemical yield and recovery of 60% in HEPES-buffered saline (pH 7.4). RadioTLC after C-18 purification indicated >95% radiochemical purity of $^{140}$Nd-DOTA-LM3. The production, purification, and labeling procedure was performed twice, where the amount of peptide relative to radioactivity was selected based upon titration. Although it would have been ideal to have all samples at identical specific activity, it was not possible, and in this case, the final radiolabeled activities for $^{140}$Nd-DOTA-LM3 were 5.0 and 2.5 MBq/nmol, each sufficient activity for relative quantifications of the HPLC effluent are shown overlaid on the HPLC to highlight the parent-daughter dechelation effect. The release of $^{140}$Pr3+ from $^{140}$Nd decaying on the column. From the trace, it was evident that the release of $^{140}$Pr from DOTA-LM3 after $^{140}$Nd decay is >95% efficient, matching the observations of Zhernosekov and co-workers (13). Furthermore, the column behavior illustrated the expected in vivo behavior: a rapid redistribution of the positron-emitting daughter after the decay of the parent.

### Ex Vivo Biodistributions of $^{140}$Nd-DOTA-LM3 and $^{140}$Nd-Chloride
Eight mice bearing dual-flank NCI-H727 lung carcinoid tumors were injected with 3–4 MBq $^{140}$Nd-DOTA-LM3: four at a specific activity of 5 MBq/nmol and four at 2.5 MBq/nmol. A further three tumor-bearing mice were injected with 3 MBq $^{140}$Nd-chloride. PET quantifications were obtained at 1, 3, and 16 h postinjection. After the last scan the animals were euthanized, and following equilibration of the daughter, the mice were rescaned. Finally, the animals were dissected, and tissue samples were weighed and counted.

For the unbound $^{140}$Nd-chloride injections, the ex vivo biodistribution (16 h) showed high levels of accumulation in the lungs, spleen and liver, and to a lesser extent bone and tumor (Figure 3). This is a typical biodistribution for free +3 oxidation state lanthanides [for femur and liver vs. tumor, see, Ref. (27)] and for other hard radiometals [e.g., see, Ref. (27)]. The tissues with high accumulation of $^{140}$Nd were also expected to accumulate released $^{140}$Pr, owing to the chemical similarities between praseodymium and neodymium. Thus, this biodistribution serves as a descriptor of which tissues we expect to exhibit “sink” behavior in the pre-mortem PET scans.

The ex vivo biodistribution of $^{140}$Nd-DOTA-LM3 was very distinct from that of $^{140}$Nd-chloride with the pancreas, a known
somatostatin receptor positive organ, being particularly interesting (21). The pancreas was found to take up $^{140}$Nd-DOTA-LM3 without accumulating the free radiometal (13% ID/g with high specific activity $^{140}$Nd-DOTA-LM3, compared to 0.1% ID/g with the free $^{140}$Nd$^{3+}$). Therefore, in the PET study, the pancreas was expected to have a lower signal in the pre-mortem $^{140}$Nd-DOTA-LM3 scans compared to the post-mortem scans. The liver, spleen, and lungs had the opposite behavior, accumulating the free radiometal but not the peptide, and were expected to have a higher signal in the pre-mortem scans than in the post-mortem.

Fani et al. showed that in comparing the biodistribution of $^{68}$Ga-NODAGA-LM3, $^{68}$Ga-DOTA-LM3, $^{64}$Cu-NODAGA-LM3, and $^{64}$Cu-CBTE2A-LM3, tumor uptake relative to the pancreas, stomach, and kidney is highly variable depending on the metal and chelator used (23, 28). In the current work, we injected 300 pmol (5 MBq/nmol) or 600 pmol (2.5 MBq/nmol) in order to get enough signal for the PET scans. For the biodistributions from Fani et al., 10 pmol was injected, and blocking was performed with 200 nmol of excess DOTA-LM3. The overall effect of the blocking was to reduce the uptake in sst2 expressing tissues, which is exactly what was observed between the higher and lower specific activity injections of the current study: a modest reduction in the uptake in sst2 expressing tissues relative to the kidney, and overall faster excretion.

Based upon the ex vivo biodistribution, the tumors had an intermediate behavior, weakly concentrating both the free $^{140}$Nd and the labeled peptide, meaning that the PET signal was expected to change little between the pre- and post-mortem scans (i.e., washout of $^{140}$Pr from the tumor volume could be compensated by uptake of $^{140}$Pr from the bloodstream). This behavior is in many ways an undesirable outcome, because signals arising from the tumors can be attributable to both the free metal ions and the targeted peptide. Future work with a different vector/target system could give a result with a simpler interpretation. Nevertheless, the pancreas remains an interesting tissue within the present set of experiments.

**PET Studies Show Tissue Dependent Redistribution of $^{140}$Pr after $^{140}$Nd Decay**

Positron emission tomography data were analyzed to quantify the $^{140}$Pr signal from the tumors, pancreas, kidney, lung, and liver (Table 1). The PET signals for the tumors are given as the percent of the injected signal per gram (%IS/g) (Figure 4). This unit is non-standard and is described further in the Supplementary Material. %IS/g was chosen for two reasons: first because the PET scans quantify the redistributed daughter $^{140}$Pr, not the $^{140}$Nd-tracer, and second because the data were not corrected for point spread due to extensive positron range. This means that there is a substantial partial volume distortion when converting from annihilation signal (%IS/g) to tracer concentration (%ID/g), and that the well-counter based ex vivo biodistribution is not directly comparable to the post mortem PET results. A discussion of the partial volume effect due to the high energy positrons from $^{140}$Pr is included in the Supplementary Material. The tumor time-activity curve shows that in this model (as expected from the ex vivo biodistribution) very little redistribution is observed.

For the present case, the tumor was known to accumulate the trivalent lanthanide to some small degree (from the Nd-chloride injection data above), meaning that $^{140}$Pr$^{3+}$ produced by decay in the tumor region had some tendency to remain. In other organs, however, due to the dechelation effect, there was a dramatic change in the PET signal in the pre- and post-mortem imaging quantifications. The redistribution effects are displayed in Figure 5 as the ratio of the mean organ signal between the post-mortem, and pre-mortem (16 h) images. This effect is most evident in the pancreas and liver for the high specific activity injections, where the decrease in liver signal is matched by an increase in the pancreas signal, confirming the behaviors of the peptide and free metal observed in the ex vivo biodistribution.

It should be noted that the injected mass of the tracer had a large effect upon the PET quantifications and ex vivo biodistribution (Figures 4 and 5). This indicates that the receptor-specific accumulation was becoming saturated as the injected mass increased from 0.5 nmol (5.0 MBq/nmol) to 1 nmol (2.5 MBq/nmol). This saturation behavior is non-desirable for probing the internalization behavior of the peptide as non-specific interactions begin to dominate the tracer distribution.

Figure 6 shows an example PET/CT reconstruction, qualitatively illustrating the redistribution effect. The most striking differences in the images between the daughter distribution (16 h, left panels) and the parent distribution (post-mortem, right panels) are seen in the liver, lungs, and pancreas. As expected, the 16 h pre-mortem PET images more closely reflected the biodistribution observed for the free $^{140}$Nd-chloride injections, while the post-mortem images showed the biodistribution for the intact $^{140}$Nd-DOTA-LM3 tracer.

The most important result from the PET imaging was the pancreatic signal. In this case, in the pre-mortem image, it was
Figure 5 | Ratio of the post-mortem positron emission tomography (PET) signal to the pre-mortem (16 h) PET signal for each tissue. Tissues with ratios greater than unity release $^{140}$Pr into circulation faster than they absorb it. $^{140}$Pr is trafficked away from the site of $^{140}$Nd decay. The pancreatic signal from the $^{140}$Nd-chloride images was masked by the high liver signal, prohibiting reliable quantification.

Figure 4 | Positron emission tomography (PET) signal in tumors as a function of time after injection with $3.3–4.3$ MBq of $^{140}$Nd-DOTA-LM3 or $2.7–3.1$ MBq of $^{140}$Nd-chloride. Values are presented as %ID/g and depicted as mean ± SEM ($^{140}$Nd-DOTA-LM3, $n = 8$ each and $^{140}$Nd-chloride, $n = 6$). Animals were anesthetized with sevoflurane during the 600 s PET acquisitions.

The tissue signal quantifications in %IS/g are given for the 16 h postinjection scans (16 h) and the post mortem scans (PM). The paired-difference t-test was used to indicate in which cases the pre- and post-mortem quantifications were significantly different, where p-values under 0.05 are displayed in bold. Each subject had two tumors, and the quantification for each is used for the computation of the tumor p-value. The high concentration of the $^{140}$Nd in the liver of subjects receiving the $^{140}$Nd-chloride injections precluded quantification of activity in the pancreas (N/Q, not quantified).

The tissue signal quantifications were significant in %IS/g, signifying that the ex vivo biodistribution revealed that the pancreas contained 13%ID/g of the tracer, which should be easily distinguishable from the 3%ID/g of the liver. This discrepancy is resolved in the post-mortem imaging, where the accumulation of the tracer in the pancreas, and not in the liver, is apparent. The effects observed are consistent with a hypothesis that $^{140}$Nd-DOTA-LM3 localized on the surface of pancreatic cells (via non-internalizing interactions with the somatostatin receptor) releases $^{140}$Pr$^{3+}$ into the bloodstream, where it is quickly redistributed to the liver, spleen and lungs. In fact, results from the higher specific activity $^{140}$Nd-DOTA-LM3 difficult to delineate the pancreas due to the elevated-background in the liver. This is despite the fact that the ex vivo biodistribution revealed that the pancreas contained 13%ID/g of the tracer: which should be easily distinguishable from the 3%ID/g of the liver. The discrepancy is resolved in the post-mortem imaging, where the accumulation of the tracer in the pancreas, and not in the liver, is apparent. The effects observed are consistent with a hypothesis that $^{140}$Nd-DOTA-LM3 localized on the surface of pancreatic cells (via non-internalizing interactions with the somatostatin receptor) releases $^{140}$Pr$^{3+}$ into the bloodstream, where it is quickly redistributed to the liver, spleen and lungs. In fact, results from the higher specific activity $^{140}$Nd-DOTA-LM3.

| Subject | 16 h PM | 16 h PM | 16 h PM | 16 h PM | 16 h PM | 16 h PM | 16 h PM | 16 h PM | 16 h PM | 16 h PM | 16 h PM | 16 h PM | 16 h PM |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| Liver   | 1       | 2       | 3       | 4       | 5       | 6       | 7       | 8       | 9       | 10      | 11      |
| Muscle  | 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| Lung    |         |         |         |         |         |         |         |         |         |         |         |         |
| L. tumor| 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| R. tumor| 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| Muscle  | 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| Lung    |         |         |         |         |         |         |         |         |         |         |         |         |
| L. tumor| 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| R. tumor| 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| Muscle  | 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| Lung    |         |         |         |         |         |         |         |         |         |         |         |         |
| L. tumor| 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| R. tumor| 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| Muscle  | 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| Lung    |         |         |         |         |         |         |         |         |         |         |         |         |
| L. tumor| 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| R. tumor| 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| Muscle  | 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| Lung    |         |         |         |         |         |         |         |         |         |         |         |         |
| L. tumor| 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| R. tumor| 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| Muscle  | 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| Lung    |         |         |         |         |         |         |         |         |         |         |         |         |
| L. tumor| 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| R. tumor| 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |
| Muscle  | 0.28    | 0.31    | 0.24    | 0.25    | 0.26    | 0.26    | 0.32    | 0.31    | 0.32    | 0.24    | 0.23    |         |

$^{140}$Nd DOTA-LM3

$^{140}$Nd DOTA-LM3

$^{140}$Nd DOTA-LM3

$^{140}$Nd DOTA-LM3

$^{140}$Nd DOTA-LM3

$^{140}$Nd DOTA-LM3

$^{140}$Nd DOTA-LM3

$^{140}$Nd DOTA-LM3

$^{140}$Nd DOTA-LM3

$^{140}$Nd DOTA-LM3
studies show that 56 ± 7% (n = 4, mean ± SD) of the in situ produced 140Pr washed out of the pancreas before decay. For statistical analysis the pre- and post-mortem PET quantifications were compared with a paired-difference two-tailed t-test. The tabulated data are presented in Table 1, along with the p values. In this case, the t-test was used to determine the significance of the absolute difference between the pre- and post-mortem signals in %IS/g. Admittedly, there are many ways to analyze these data, and in this case, the paired-difference test was selected because it adds to the statistical power by comparing the tissues in a single subject to themselves after intervention. Clearly from the p values in Table 1, the use of DOTA-LM3 as a tracer led to significant changes from the pre- to post-mortem images, while the non-targeted 140Nd-chloride injections, is that the only tissue with a statistically significant difference between the pre- and post-mortem quantification is the kidney, whereas in the targeted DOTA-LM3 images the only tissue lacking a significant difference was the muscle. The kidney is interesting because in all cases the post-mortem signal was higher, by 25–50% than the pre-mortem value. While it could be suggested that this is due to rapid excretion of 140Pr3+ from the kidney to the bladder in vivo, the fact that this is also observed with the 140Nd-chloride injections indicates that within the kidney the chemical form of the neodymium is not necessarily as a free cationic lanthanide. However, in all other tissues, the distribution of 140Nd from the 140Nd-chloride injections strongly resembles that of redistributed 140Pr.

The pancreatic washout reveals a potential benefit derived from the 140Pr's delayed positron. Specifically, the degree of redistribution of 140Pr3+ may be affected by its location and access to blood flow. This means that the PET signal observed with 140Nd labeled vectors might be highly dependent on their cellular internalization status, as 140Pr3+ cations originating from decays occurring on the surface of the cell or in circulation may be transported away by the blood flow, whereas 140Pr3+ cations released from 140Nd decay inside of a cell have an additional diffusion barrier. A conceptual graphic demonstrating the idea is depicted in Figure 7. As many promising new classes of pharmaceuticals, in particular nanoparticle drug formulations, gene therapy and targeted Auger emitting radionuclides, are expected to be most effective when internalized, a PET radiolabel for determining internalization would be a valuable tool for drug development.

General Discussion
When searching for long-lived PET radionuclides, the utility of 140Nd is immediately evident in its half-life and lack of concurrent gamma emissions. However, due to the nature of the delayed positron from the short-lived daughter, it is important to understand how imaging may be affected by dechelation. The redistribution of 140Pr in the present case was clearly visible in the pre- and post-mortem PET images. While the tumor signal was significantly changed, the magnitude of change was small which may preclude application. However, this behavior might be model dependent, and not general for all tumor types or locations. Nevertheless, the signals from the other tissues show the potential for using the daughter-delay to determine the in vivo internalization status of new probes, as highlighted by the pancreatic signal. These data support a hypothesis that in certain cases, PET imaging with 140Nd provides a localized signal only if a vector is internalized. This capability may prove useful in future drug development where in vivo internalization is critical for drug action.
**CONCLUSION**

In this study, we showed that the non-internalizing tracer $^{140}$Nd-DOTA-LM3 accumulates in the pancreas and releases $^{140}$Pr into the blood stream where it quickly redistributes to the liver and lungs. We hope that further work will lead to the development of internalization sensitive PET probes using $^{140}$Nd as the radiolabel. The experimental set up described here with pre- and post-mortem imaging should facilitate that development as it allows direct quantification of the parent ($^{140}$Nd, post-mortem) and daughter ($^{140}$Pr, pre-mortem) in the same subject. The ability to determine the tissue-dependent internalization of pharmaceuticals using PET would aid greatly in drug delivery designs where cellular internalization is crucial to drug action.

**ETHICS STATEMENT**

All animal experiments were performed under a protocol approved by the National Animal Experiments Inspectorate of Denmark.

**AUTHOR CONTRIBUTIONS**

GS, LK, CN, KMJ, and UK initiated the project and conceived the experiments. UK and KJ coordinated and performed production and collections of $^{140}$Nd from ISOLDE-CERN. GS, JF, AJ, and AF prepared and performed the radiochemistry and quality control. LK and CN performed the *in vivo* and *ex vivo* work. GS, LK, CN, AJ, JF, HM, DJ, AK, KMJ, and KJ contributed in the interpretation of results and final design of experiments. All authors provided critical input into the final work and approve of its publication.

**ACKNOWLEDGMENTS**

The authors would like to thank Dr. Etienne Vermeulen from the Paul Scherrer Institute for depositing the zinc layer onto the gold foils, and for shift operations at ISOLDE alongside Matthias Mikkelsen and Lars Emil Gutt from the Niels Bohr institute. Additionally, we would like to thank CERN/ISOLDE for making beam time available. Financial support was provided by the ENSAR (EU FP7 framework, contract 262010) and MATHIAS (EU FP7 framework) grants, the John and Birthe Meyer Foundation, Novo Nordisk Foundation, Lundbeck Foundation, AP Møller Foundation, Svend Andersen Foundation, the Arvid Nilsson Foundation, Research Council for Independent Research, Research Council of Rigshospitalet, and Research Foundation of the Capital Region of Denmark.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fmed.2017.00098/full#supplementary-material.
REFERENCES

1. Grünberg J, Lindenblatt D, Dorrer H, Cohrs S, Zhernosekov K, Köster U, et al. Anti-LiCAM radioimmunotherapy is more effective with the radiolanthane terbium-161 compared to lutetium-177 in an ovarian cancer model. *Eur J Nucl Med Mol Imaging* (2014) 41:1907–15. doi:10.1007/s00259-014-2798-3

2. Müller C, Reber J, Haller S, Dorrer H, Bernhardt P, Zhernosekov K, et al. Direct in vitro and in vivo comparison of 140Nd and 140Pr using a tumour-targeting folate conjugate. *Eur J Nucl Med Mol Imaging* (2014) 41:476–85. doi:10.1007/s00259-013-2563-z

3. Müller C, Zhernosekov K, Köster U, Johnston K, Dorrer H, Hohn A, et al. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative. *J Nucl Med* (2012) 53:1951–9. doi:10.2967/jnumed.112.107540

4. Bockisch A. Matched pairs for radionuclide-based imaging and therapy. *Eur J Nucl Med Mol Imaging* (2011) 38:1780–2. doi:10.1007/s00259-011-1780-6

5. Uusijärvi H, Bernhardt P, Rösch F, Maacke HR, Forssell-Aronsson E. Electron- and positron-emitting radiolanthanes for therapy: aspects of dosimetry and production. *J Nucl Med* (2006) 47:807–14.

6. Nica N. Nuclear data sheets for A = 140. *Nucl Data Sheets* (2006) 108:1287–470. doi:10.1016/j.nds.2007.06.001

7. Mausner L. The in vivo generator for radioimmunotherapy. *J Label Compd Chem* (1989) 28:395–500. doi:10.1002/jlcc.2850260121

8. Edem PE, Fonslet J, Kjaer A, Herth M, Severin G. In vivo radionuclide generators for diagnostics and therapy. *Bioinorg Chem Appl* (2016) 2016:6148357. doi:10.1155/2016/6148357

9. Rösch F, Forssell-Aronsson E. Radiolanthanes in nuclear medicine. *Met Ions Biol Syst* (2004) 42:77–108.

10. Hansen AE, Petersen AL, Henriksen JR, Boerresen B, Rasmussen P, et al. Positron emission tomography based elucidation of the enhanced permeability and retention effect in dogs with cancer using 188Re-DOTA-LM3, 188Re-DOTA-OH and 188Re-DOTA-PE. *Nucl Med Biol* (2004) 31:135–41. doi:10.1016/j.nucmedbio.2003.09.007

11. Fani M, Del Pozzo L, Abiraj K, Mansi R, Tamma ML, Cescato R, et al. PET of somatostatin receptor-positive tumors using 188Re- and 186Re-somatostatin antagonists: the chelate makes the difference. *J Nucl Med* (2011) 52:1118–20. doi:10.2967/jnumed.111.087999

12. Kraus KA, Nelson F. Anion exchange studies of the fission products. *Nucl Data Sheets* (1990) 26:111–4. doi:10.1016/0029-554x(90)90080-7

13. Zhernosekov KP, Filosov DV, Quam SM, Rösch F. A 140Nd/140Pr radionuclide generator based on physico-chemical transitions in 140Pr complexes after electron capture decay of 140Nd-DOTA. *Radiochim Acta* (2007) 95:319–27. doi:10.1524/ract.2007.95.6.319

14. Yakushev EA, Kovalik A, Filosov DV, Korolev NA, Lebedev NA, Lubashvskia V, et al. An experimental comparison of the K- and L-Auger electron spectra generated in the decays of 144Nd and 144In. *Appl Radiat Isot* (2005) 62:451–6. doi:10.1016/j.apradiso.2004.06.012

15. Köster U. ISOLDE target and ion source chemistry. *Radiochim Acta* (2001) 89:79–56. doi:10.1524/ract.2001.89.11-12.749

16. Beyer GI, Ruth TJ. The role of electromagnetic separators in the production of radiotracers for bio-medical research and nuclear medical application. *Nucl Instrum Methods Phys Res B* (2003) 204:694–700. doi:10.1016/S0168-583X(03)00489-0

17. Müller C, Reber J, Haller S, Dorrer H, Köster U, Johnston K, et al. Folate receptor targeted alpha-therapy using terbium-149. *Pharmaceuticals* (Basel) (2014) 7:353–65. doi:10.3390/ph7030353

18. Müller C, Vermeulen C, Köster U, Johnston K, Türlar A, Schibli R, et al. Alpha-PET with terbium-149: evidence and perspectives for radiotherapy diagnostics. *EJNMMI Radiopharm Chem* (2017) 1:5. doi:10.1186/s41181-016-0008-2

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Severin, Kristensen, Nielsens, Fonslet, Jensen, Freilse, Jensen, Elema, Maacke, Kjaer, Johnston and Köster. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.